Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 736.11M |
| Revenue (ttm) | 175.51M |
| Net Income (ttm) | -78.02M |
| Shares Out | 144.62M |
| EPS (ttm) | -0.54 |
| PE Ratio | n/a |
| Forward PE | 128.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 903,857 |
| Open | 5.02 |
| Previous Close | 5.05 |
| Day's Range | 5.02 - 5.16 |
| 52-Week Range | 4.71 - 12.43 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 10.33 (+102.95%) |
| Earnings Date | May 2, 2024 |
About AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. [Read more]
Financial Performance
In 2023, AUPH's revenue was $175.51 million, an increase of 30.95% compared to the previous year's $134.03 million. Losses were -$78.02 million, -27.88% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 102.95% from the latest price.
News
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference.
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024.
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference.
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program.
Aurinia to Participate in Upcoming Investor Healthcare Conferences
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.
Aurinia Pharmaceuticals shares plummet amid failed buyer hunt, 25% employee layoff plans
U.S.-listed shares of Aurinia Pharmaceuticals (AUPH.O) witnessed a significant downturn, plummeting 25% to $6 in pre-market trading. The pharmaceutical company announced the conclusion of its strategi...
Aurinia to stop development of immunotherapies after strategic review
Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thurs...
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year busines...
Exclusive: Kidney drug developer Aurinia fails to clinch a sale, sources say
Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost ...
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024.
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results.
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200.
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan.
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with LN at ACR 2023.
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis.
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS.
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis.
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
EDMONTON, Alberta--(BUSINESS WIRE)--Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) The updated release reads: AURINIA PHARMACEUTICALS TO RELEASE ...
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of...
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory...
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital.
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership.
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts ar...
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023.
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 e...